You are here

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
Early initiation of antiretroviral therapy prevents HIV transmission to seronegative sexual partners
  1. George W Rutherford1,
  2. Andrew Anglemyer2
  1. 1Global Health Sciences, University of California, San Francisco, San Francisco, California, USA
  2. 2Department of Operations Research, Naval Postgraduate School, Monterey, California, USA
  1. Correspondence to : Professor George W Rutherford, Global Health Sciences, University of California, San Francisco, 550 16th Street, Box 1224, San Francisco, CA 94143-1224, USA; george.tutherford{at}ucsf.edu

https://doi.org/10.1136/ebmed-2016-110576

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016;375:830–9OpenUrlCrossRefPubMed.

    Context

    In 2011, interim results from the HIV Prevention Trials Network (HPTN) 052 trial confirmed that early antiretroviral therapy (ART) markedly reduces HIV transmission in serodiscordant couples.1 This, along with evidence that therapeutic benefits accrue from starting ART earlier,1–3 led the WHO to recommend that all patients with HIV infection start ART as soon as possible after diagnosis.4 Cohen et al have now published a final analysis from their original HPTN 052 report.

    Methods

    The HPTN 052 trial randomised ART-naïve participants to initiate ART early, between 350 and 550 CD4 cells/µL, or to delay initiation until 250 cells/µL. Uninfected primary …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.